Ezra Klein

Yeah.

My assumption of why some people were getting anhedonia, some people were seeing lower desire for drinking, was actually not necessarily that it would end up proving to be a clear treatment.

but that it is messing with a system we don't really understand.

I mean, I sort of think what's interesting about this whole conversation is we're basically saying we don't understand any of the systems very well.

We don't understand the appetite system.

It's working a different way than we hypothesized.

The cardiac system is not doing what we thought it would be doing.

We don't know why the inflammation system is responding.

The reward system is changing.

I mean, the human body is a very, very, very complex set of systems.

And this seems to be a complex change to them that at the population level is positive, probably, but not in a way where we can precisely define the mechanisms by which it is positive or tell you for whom it will be positive, for whom it will be negative, and who will actually lose weight and who won't and how much.

It's a very weird thing.

space actually.

What about all the drugs that are coming now?

So I know people who are getting retitutride from some compounding pharmacy in China or something.

And retitutride, maybe you can explain it, but it's another Eli Lilly drug.

Eli Lilly also makes Zepound, the trisepatide variant.

And this is in trials now, and it's expected that it will be approved in the next some amount of time, and it'll probably be a big deal.

But

It works even better than the other two.